| Characteristic | Training cohort (n = 137) | P | Independent validation cohort (n = 54) | P |
|---|
| pGR (n = 57) | Non-pGR (n = 80) | pGR (n = 25) | Non-pGR (n = 29) |
|---|
| Age, years |
| Median (range) | 16 (4.6–43) | 14 (4–46) | 0.3939 | 15 (8–39) | 18 (7–44) | 0.6123 |
| ≤ 15 y | 27 | 45 | | 13 | 12 | |
| > 15 y | 30 | 35 | | 12 | 17 | |
| Gender | | | 1 | | | 0.5852 |
| Male | 34 | 47 | | 14 | 13 | |
| Female | 23 | 33 | | 11 | 16 | |
| Location of primary tumor | | | 0.3447 | | | 0.8041 |
| Humerus | 11 | 8 | | 3 | 3 | |
| Femur | 27 | 45 | | 14 | 17 | |
| Tibia and fibula | 17 | 20 | | 8 | 8 | |
| Radius and ulna | 1 | 2 | | 0 | 0 | |
| Others | 1 | 5 | | 0 | 1 | |
| Stage at diagnosis | | | 1 | | | 0.3062 |
| Localized | 47 | 66 | | 20 | 27 | |
| Metastatic | 10 | 14 | | 5 | 2 | |
| Pathologic subtype | | | 0.3055 | | | 0.332 |
| Osteoblastic | 46 | 55 | | 20 | 19 | |
| Chondroblastic | 3 | 13 | | 1 | 5 | |
| Fibroblastic | 4 | 4 | | 4 | 4 | |
| Telangiectatic | 3 | 5 | | 0 | 1 | |
| Others | 1 | 3 | | 0 | 0 | |
| Type of surgery | | | 0.02487* | | | 1 |
| Limb salvage | 55 | 66 | | 24 | 27 | |
| Amputation | 2 | 14 | | 1 | 2 | |
| New pulmonary metastasis | | | 1 | | | 0.9402 |
| Yes | 2 | 4 | | 1 | 0 | |
| No | 55 | 76 | | 24 | 29 | |
| Chemotherapy regimens | | | 0.7224 | | | 0.4406 |
| 1MTX, DDP and ADM | 42 | 58 | | 17 | 22 | |
| 2MTX, IFO,DDP and ADM | 12 | 15 | | 8 | 6 | |
| 3MTX,IFO, DDP and ADM | 3 | 7 | | 0 | 1 | |
| Radiomics score | 4.4E-4(−1.1–0.72) | −0.55(−2.9–0.32) | 2.1E-14 | 0.030(−0.58–0.71) | −0.31(−2.1–0.34) | 2.4E-5 |
- Note: Individual clinical factors were analyzed for significant differences using a nonparametric test. *P < 0.05 indicates a significant difference. Ages and radiomics scores are represented as [Median (range)]. Methotrexate (MTX), Ifosfamide (IFO), Cisplatin (DDP) and Doxorubicin (ADM)
